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Abstract
Introduction Complete resection is the most important
prognostic factor in surgery for pelvic tumors. In locally
advanced and recurrent pelvic malignancies, radical mar-
gins are sometimes difficult to obtain because of close
relation to or growth in adjacent organs/structures. Total
pelvic exenteration (TPE) is an exenterative operation for
these advanced tumors and involves en bloc resection of
the rectum, bladder, and internal genital organs (prostate/
seminal vesicles or uterus, ovaries and/or vagina).
Methods Between 1994 and 2008, a TPE was performed
in 69 patients with pelvic cancer; 48 with rectal cancer (32
primary and 16 recurrent), 14 with cervical cancer (1 pri-
mary and 13 recurrent), 5 with sarcoma (3 primary and 2
recurrent), 1 with primary vaginal, and 1 with recurrent
endometrial carcinoma. Ten patients were treated with
neoadjuvant chemotherapy and 66 patients with preopera-
tive radiotherapy to induce down-staging. Eighteen patients
received IORT because of an incomplete or marginal
complete resection.
Results The median follow-up was 43 (range, 1–196)
months. Median duration of surgery was 448 (range, 300–
670) minutes, median blood loss was 6,300 (range, 750–
21,000) ml, and hospitalization was 17 (range, 4–65) days.
Overall major and minor complication rates were 34% and
57%, respectively. The in-hospital mortality rate was 1%.
A complete resection was possible in 75% of all patients, a
microscopically incomplete resection (R1) in 16%, and a
macroscopically incomplete resection (R2) in 9%. Five-
year local control for primary locally advanced rectal
cancer, recurrent rectal cancer, and cervical cancer was
89%, 38%, and 64%, respectively. Overall survival after
5 years for primary locally advanced rectal cancer, recur-
rent rectal cancer, and cervical cancer was 66%, 8%, and
45%.
Conclusions Total pelvic exenteration is accompanied
with considerable morbidity, but good local control and
acceptable overall survival justifies the use of this exten-
sive surgical technique in most patients, especially patients
with primary locally advanced rectal cancer and recurrent
cervical cancer.
Introduction
Locally advanced pelvic tumors without distant metastases
can cause severe local problems, such as pain, voiding, and
defecation problems, and may result in a decreased quality
of life [1, 2]. Extensive surgery often is the only possibility
for complete resection, thereby attempting to provide local
control and palliation. In case of involvement of the base or
trigone of the bladder or the prostate, a total pelvic exen-
teration (TPE) with resection of the rectum together with
bladder, lower ureters, and internal genital organs could
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potentially salvage the patient [3]. After resection of the
bladder, an ileal conduit is usually constructed according to
the technique described by Bricker [4]. TPE has been
performed in primary or recurrent cancer of the cervix,
rectum, vagina, uterine corpus, vulva, prostate, bladder,
and for pelvic sarcoma [5, 6].
Since the introduction of the technique by Brunswick in
1948, the initially poor quality of life and high mortality and
morbidity associated with the technique have substantially
improved [7–9]. However, morbidity after this extensive
surgical procedure is still high and reported to be between
13% and 64% [10–12]. Five-year survival rates after TPE
for patients with primary disease range between 32% and
66% and in patients with recurrent disease from 0% to 23%
[3, 7, 12]. Hence, a careful selection in a multidisciplinary
setting of patients is of paramount importance.
In the present study, all patients who underwent a pelvic
exenteration were reviewed. Preoperative morbidity and
mortality, local recurrence, disease-free, and overall sur-
vival rates were studied and prognostic factors for local
control or survival were analyzed.
Patients and methods
In the Erasmus University Medical Center-Daniel den
Hoed Cancer Center, 69 TPEs were performed during the
period from 1994 to 2008 for locally advanced primary or
locally recurrent pelvic malignancies. Forty-eight patients
with rectal cancer (32 primary locally advanced and 16
recurrent), 14 with cervical cancer (1 primary and 13
recurrent), 5 with pelvic sarcoma (3 primary and 2 recur-
rent), 1 with primary vagina carcinoma, and 1 with recur-
rent endometrial carcinoma. Fifty patients were men, with
a median age of 61 (range, 30–76) years.
Patients were preoperatively analyzed and selected
using CT or MRI scanning, or both, of the small pelvis
(90% and 59%, respectively). On indication, a cystoscopy
was performed to rule out or establish bladder involvement.
Screening for distant metastases was performed using
thoracic and abdominal CT scan in all patients.
All 32 patients with primary rectal cancer received 50 Gy
preoperative (chemo)radiation. Thirteen of 26 patients (10
cervical, 2 sarcoma, and 1 rectal cancer patient) with
recurrent cancer previously received radiotherapy during
treatment of the primary tumor (median dosage, 50 (range,
46–60) Gy. One patient was re-irradiated (27 Gy) after
50 Gy adjuvant radiation after primary treatment for rectal
cancer. One patient with recurrent rectal cancer received
chemotherapy as primary treatment. Primary treatment for
patients with recurrent cancer is described in Table 1.
In 1997 an intraoperative radiation therapy (IORT)
program was started in our hospital and the technique was
described previously [13]. Briefly, IORT with HDR
brachytherapy was given to patients who had a minimal
circumferential-free resection margin B2 mm. The resec-
tion margin was judged on frozen sections taken during
surgery. IORT was performed using the Flexible Intraop-
erative Template (FIT) developed at our department,
delivering a dose of 10 Gy, usually at 1-cm depth from the
applicator surface.
Pathology
All staging, except from the staging of sarcoma, was per-
formed according to the AJCC TNM criteria, and com-
pleteness of resection was divided in R0 (complete
resection of tumor), R1 (microscopic tumor remnant in
circumferential margin), and R2 (macroscopically not
complete resection). Recurrent rectal tumors were staged
according to the Wanebo classification for recurrent tumors
[14]. Since 2002, all pathology examinations for rectal
cancer have been performed according to the guidelines of
Quirke et al. [15].
Evaluation of morbidity and mortality
Hospital charts were studied to collect patient character-
istics, operation techniques, and follow-up. Surgery-related
morbidity was divided into major and minor complications.
Major morbidity was defined as a complication that
requires (surgical) reintervention. All other complications
were classified as minor.
Statistical analysis of survival and local control
Survival time was calculated from the date of resection of
the tumor until the last follow-up attendance or until death.
Local control was calculated from the date of resection
until the histological or evident radiological presence of a
local recurrence. The cumulative survival and local control
rate after surgery were calculated using the Kaplan–Meier
Table 1 Previous procedures of patients with recurrent pelvic cancer
Rectal (n = 16) Abdominal perineal resection 8
Low anterior resection 5
Rectosigmoid resection and end
colostomy
3
Cervical (n = 13) Radical hysterectomy 7
Extrafascial abdominal hysterectomy 3
Vaginal hysterectomy 1
Chemoradiation 2
Sarcoma (n = 2) Local excision 1
Hysterectomy 1
Endometrial (n = 1) Abdominal uterus extirpation 1
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method [16]. Univariate survival comparisons were exe-
cuted using the log-rank test. Cox proportional hazards
analysis was used for multivariate analysis of prognostic
factors for local control and overall survival [17]. The level
of significance was defined as p \ 0.05.
Results
At the time of diagnosis patients presented with complaints
of pain (19%), changes in defecation (25%), changes in
urinary miction (7%), perineal pressure (6%), and a com-
bination of these complaints (33%). Only seven patients
(10%) did not have complaints and were diagnosed during
routine follow-up.
At the preoperative physical examination, 47% of the
gynecological tumors were clinically fixed to the rectum
and 74% percent of the rectal tumors were clinically fixed
to the prostate and bladder.
An exploratory staging laparotomy to create a colos-
tomy or ileostomy was performed in 15 patients (1 sar-
coma, 1 recurrent cervical, 12 primary locally advanced,
and 1 recurrent rectal cancer). No distant metastases were
found during previous surgery and preoperative screening.
Preoperative treatment
Ten patients (14%) received neoadjuvant chemotherapy (5
rectal cancer, 1 primary, 3 recurrent cervical, and 1 vagina
carcinoma). Forty-six patients (67%) received preoperative
radiotherapy (median dosage, 50 (range, 27–67) Gy).
Surgery
The median duration of surgery was 448 (range, 300–670)
minutes. The median blood loss was 6,300 (range, 750–
21,000) ml. Fifty-eight patients received a small bowel as
urostoma and 11 patients a colon conduit. None of the
patients had liver or diffuse peritoneal metastatic disease.
In all but six patients, an omentoplasty, and in five patients,
an unilateral gracilis muscle transposition was used for
primary pelvic reconstruction. Indirect reconstruction with
gracilis transposition (one bilateral and three unilateral)
was performed in three patients because of persistent per-
ineal wounds. No flap necrosis occurred and eventually
after secondary reconstruction all perineal wounds closed
in a median of 86 (range, 43–304) days.
Intraoperative and postoperative treatment
IORT was applied in 18 patients (6 primary rectal, 10
recurrent rectal, 2 recurrent cervical cancer): 8 with a
marginal radical (R0) resection, 9 with a microscopically
irradical resection (R1), and 1 with macroscopic tumor
mass (R2). One primary sarcoma and two recurrent cervi-
cal tumors were postoperatively irradiated. None of the
patients received adjuvant chemotherapy.
Postoperative
TNM and Wanebo stages and completeness of resection
are depicted in Table 2. All sarcomas underwent a com-
plete resection. The TNM stage for one vagina carcinoma
was T4N0 and T3N0 for the recurrent endometrial carci-
noma. Both tumors were resected complete. The median
postoperative hospital stay was 17 (range, 4–65) days with
an increase for the recurrent tumors compared to the pri-
mary-treated tumors (20 vs. 14 days).
Complications are depicted in Table 3. The most com-
mon minor complications were a superficial wound infec-
tion (34%) and pulmonary infections (8%). Forty-eight
percent of all reinterventions were performed because of
complications related to the construction of the urostomy.
All of these patients had received radiotherapy (1 in pri-
mary treatment, 9 in neoadjuvant setting, and 1 in previous
treatment, intraoperatively as in adjuvant treatment).
The major and minor complication rates were not sig-
nificantly different for patients treated with or without
radiotherapy.
Table 2 Pathology characteristics
Rectal Cervical
Prim Rec Prim Rec
Total no. (32) (16) (1) (13)
T stage T0 – 8%a – 9%
T2 – – – 9%
T3 35% 25%b – 36%
T4 65% 67%c 100% 45%
N stage N0 57% 42% 100% 45%
N1 9% 16% – –
N2 9% – – –
Nx 26% 42% – 54%
Completeness R0 82% 58% 100% 64%
R1 9% 25% – 36%
R2 9% 17% – –
a Wanebo classification for recurrent rectal cancer stage Tr 0 (no
recurrence)
b Wanebo classification for recurrent rectal cancer stage Tr 3 (growth
into surrounding soft tissue)
c Wanebo classification for recurrent rectal cancer stage Tr 4 (pen-
etration anterior structures)
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Local control
The 5-year local control of primary rectal, recurrent rectal,
and other cancer was 89%, 38%, and 64% (Fig. 1). All four
patients with a soft-tissue sarcoma and the patients with a
primary cervical tumor and primary vaginal tumor
remained without local recurrence after 5 years. A recur-
rence at the urethra was observed 10 months after resection
in the patient who was operated for a third recurrence of an
endometrial tumor. The recurrence was treated with local
palliative resection and the patient received systemic
chemotherapy.
At univariate analysis, significant prognostic factors for
an improved local control were the interval from primary
resection to local recurrence more than 12 months
(p = 0.012), type of tumor (primary rectal; p = 0.009),
Table 3 Complications and reinterventions
Prim rectum (n = 32) Rec rectum (n = 16) Cervix (n = 14) Others (n = 7) Total (n = 69)
Complications
Minor only 12 (38%) 5 (31%) 2 (14%) 3 (43%) 22 (32%)
Major only – 4 (25%) – – 4 (6%)
Major and minor 9 (28%) 4 (25%) 6 (43%) 1 (14%) 20 (29%)
No complication 11 (34%) 3 (18%) 6 (43%) 3 (43%) 23 (33%
Minor complications
Wound infection perineal 4 (12%) 1 (6%) 3 (21%) 2 (28%) 10 (14%)
Wound infection midline 6 (19%) 3 (19%) 3 (21%) 1 (14%) 13 (19%)
Pneumonia 4 (12%) 1 (6%) 1 (7%) 1 (14%) 7 (10%)
Central venous catheter sepsis 1 (3%) 1 (6%) – – 2 (3%)
Fever without known cause 1 (3%) – – – 1 (1%)
Urinary tract infection 3 (9%) – 2 (14%) 1 (14%) 6 (9%)
Neuropathy 1 (3%) 1 (6%) – – 2 (3%)
TIA – 1 (6%) – – 1 (1%)
Decubitus 1 (3%) 1 (6%) – – 2 (3%)
Major complications / required reintervention
Urostomy-related
Nefrodrain placement 2 (6%) 2 (13%) 2 (14%) – 6 (9%)
Small-bowel leakage-repair 2 (6%) 1 (6%) 1 (7%) – 4 (6%)
Reimplantation ureter 1 (3%) – 1 (7%) – 2 (3%)
Other
Gracilis flap wound-repair 2 (6%) – – – 1 (1%)
Sartorius flap fistula repair – 1 (6%) – – 1 (1%)
Abdominal dehiscence repair 1 (3%) – – – 1 (1%)
Ileus relaparotomy – 1 (6%) – – 1 (1%)
Bleeding relaparotomy – – – 1 (14%) 1 (1%)
Abscess drainage – 2 (12%) 3 (21%) 1 (14%) 6 (9%)
Suture leakage repair (ileostomy) – – 1 (7%) – 1 (1%)
Enterocutaneous fistula repair – – 1 (7%) – 1 (1%)
Major complication: a complication that causes the need for reintervention or is the cause of prolonged hospitalization
Minor complication: a complication that does not cause the need for reintervention or is the cause of prolonged hospitalization
P=0.009
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Fig. 1 Kaplan–Meier curve for local control
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completeness of resection (p \ 0.001), and absence of
preoperative pain (p \ 0.001). Sex, age, preoperative
radiotherapy, and positive lymph nodes did not have
prognostic value on local control.
Overall survival
The 5-year overall survival of patients with primary,
recurrent rectal, and other cancer was 66%, 8%, and 45%
(Fig. 2). All patients with soft-tissue sarcoma were alive
after 5 years. At the last follow-up, 46 months after
resection, the patient with primary cervical cancer was
alive without evidence of disease. The patient with a pri-
mary vaginal tumor remained under local control but
developed bone metastases 16 months after TPE and died
6 months later. The patient with the third recurrence of
endometrial cancer was lost to follow-up 9 months after
developing a local recurrence.
An interval from primary resection to local recurrence of
more than 12 months, type of tumor (primary rectum), and
completeness of resection were prognostic factors for
improved survival (p = 0.01, p = 0.01, and p \ 0.001,
respectively). Sex, age, preoperative radiotherapy, and
positive lymph nodes did not have prognostic value on
overall survival.
Discussion
The technique of total pelvic exenteration was introduced
as a palliative procedure for patients with advanced gyne-
cological cancer. Currently it is performed with curative
intent in the treatment of locally advanced and recurrent
pelvic disease (rectal, cervical, endometrial, vaginal, vulvar
tumors, and soft-tissue sarcoma) [8]. In locally advanced
tumors (without distant metastasis), complete resection is
the only possibility for cure, and in patients with rectal
cancer, the overall survival rate of 66% and local control
rate of 89% after 5 years shows that survival with excellent
local control is possible after TPE [10, 12, 13]. These
results combined with the high R0 rate and acceptable
complication rate justify the performance of TPE in this
subgroup [3]. The results of TPE for recurrent rectal can-
cer, with local control of 38% and 8% overall survival after
5 years, indicate the poor prognosis and questionable
benefit of major surgery in this group. These results are
comparable with rates after nonexenterative surgery for
recurrent rectal cancer and the high occurrence of distant
metastasis emphasizes the importance of thorough patient
selection [5, 10, 12, 13].
The majority of TPE in gynecological cancer is per-
formed in recurrent cervical cancer [18–20]. The treatment
of choice for locally advanced cervical cancer is chemo-
radiation. One-third of patients with primary carcinoma of
the cervix will have residual disease or recurrent disease,
and in up to 25% of these patients there is only local dis-
ease without systemic metastases [21]. The treatment for
recurrent cervical cancer can be chemoradiation, and in a
selected population, without distant metastases, exentera-
tive surgery (posterior, anterior, or total exenteration).
However, this extensive, disfiguring procedure with a rel-
atively high complication rate should only be performed in
highly motivated patients. The 5-year overall survival after
treatment of recurrent cervical cancer of 45% in the present
study compares to rates reported in the last decade varying
from 24–54% [18, 19, 22]. This also holds true for local
recurrence-free rate of 64% after 5 years, which is com-
parable with rates varying from 40–78% in the literature
[18, 22]. For more uncommon tumors, case reports or small
series describe different results. Barakat et al. described
that surgery for recurrent endometrial cancer is associated
with only 20% long-term survival and high morbidity [23].
Preoperatively irradiated patients with locally advanced
vaginal cancer are appropriate candidates for TPE with
[50% survival after 5 years according to Berek et al [19].
Pelvic sarcomas are rare tumors that originate from the
stroma of pelvic viscera or from the retroperitoneum.
Complete resection and tumor grade are the main prog-
nostic factors for survival [24]. The four patients with
sarcomas (2 primary and 2 recurrent) in the present study
were all completely resected and did not recur in the pelvis.
The 100% overall survival without local relapse in this
small cohort compares favorably to the 66% survival after
2 years, which recently described by Lopes et al [6]. Above
all, surgery is the only option in these kinds of tumors
because there is no clear benefit of any kind of
chemotherapy.
Overall complete resection rate in the present study was
75% for all tumors. The curative potential of resection
P=0.01
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Fig. 2 Kaplan–Meier curve for overall survival
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differs between primary and recurrent tumors. A complete
resection in patients with recurrent disease was possible in
65% of the patients in the present study, which was sub-
stantially lower than for patients with a primary tumor
(85%). Complete resection is more difficult in recurrent
cancer because of primary resection of visceral fascia.
Successful complete resection of recurrent disease often is
restricted to selected patients, for example with early-
detected or limited tumor mass. As described in previous
reports, complete resection of tumor is a significant prog-
nostic factor for local control and survival [5, 10, 12, 25].
All four patients with a macroscopically incomplete
resection (2 primary and 2 recurrent rectal cancer) died
during follow-up, with a mean survival of 13 months.
Morbidity rates reported after TPE for primary and locally
recurrent rectal cancer vary from 13–78% [10, 11, 26]. We
have previously reported overall morbidity rates of 61% in
primary rectal cancer (26% major and 35% minor) and 83%
in recurrent rectal cancer (50% major and 58% minor) [3].
Infectious complications, such as midline (14%) and peri-
neal (19%) wound infection, fistula (4%), and abscesses
(12%), are the most common complications after TPE.
Preoperative radiotherapy did not lead to an increase in
complications, which is in contrast to what has been
described by Lopez et al., who identified significant higher
complication rates in the irradiated group of patients [27].
Thirty-eight percent of all major complications were
related to the construction of the urinary conduit. Houve-
naeghel et al. [28] showed similar complications (42%)
related to the construction of a noncontinent urostomy.
High complication rates after construction of a Bricker
urostomy in irradiated patients often have been reported
because of postradiation fibrosis. The Bricker procedure
remains the most performed technique for urinary diver-
sion. Other procedures using intestinal segment outside of
the radiation field, such as jejunum or colon, have been
proposed; however, each have their own related compli-
cations. Use of jejunum can lead to metabolic complica-
tions and colon conduits are reserved for patients without
previous colon resection to prevent absorption problems
[29, 30]. The use of continent pouches is increasingly
reported, with related functional advantages leading to
improved quality of life but also have 46% pouch-related
complications [30].
For many years, age was considered a contraindication
for the performance of TPE. In the present study, patients
older than aged 70 years had a similar outcome after TPE
compared with younger patients, which is confirmed by
other recent studies [20, 22]. Not age but physical condi-
tion and comorbidities are considered important criteria in
selecting patients for TPE.
As a specialized cancer center, a weekly multidisci-
plinary meeting is held. All patients with pelvic tumors are
presented and the treatment program for each individual
patient is discussed and planned.
Conclusions
Total pelvic exenteration is accompanied with considerable
morbidity; however, good local control and acceptable
overall survival justifies the use of this extensive surgical
technique in selected patients with primary locally
advanced and recurrent pelvic tumors.
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